Plain-English translation of NCT05353530 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new immunotherapy called 8R-70CAR T cell therapy for patients with newly diagnosed glioblastoma (a serious type of brain cancer). Researchers take immune cells from your blood, modify them in the laboratory to recognize and attack cancer cells, and then give them back to you as a single infusion. The goal is to see if this treatment is safe and whether it helps control the cancer after you've completed standard surgery and radiation therapy.
Glioblastoma is a very aggressive brain cancer, and even with surgery and radiation, patients often have poor outcomes. This medication is being tested because researchers believe that teaching the immune system to specifically target cancer cells could improve survival and quality of life for patients with this disease.
You likely qualify if…
You likely don't qualify if…
You will have blood drawn to collect immune cells, which researchers will modify in the laboratory over several weeks. In the meantime, you will receive standard chemotherapy and radiation therapy as planned. About 2 weeks after radiation ends, you will return to the hospital to receive a single intravenous infusion of your modified immune cells. Researchers will then monitor you closely with blood tests, scans, and clinical visits to watch for side effects and to see how well the treatment works. The trial follows a careful step-by-step approach, starting with lower cell doses and increasing them only if the treatment is safe.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
United States
Phase
Safety & dosing
Sponsor
University of Florida
Collaborators
AM Rosen Foundation
Enrollment target
~39 participants
Started
July 2023
Primary completion
December 2027
Age range
18 Years – 80 Years
Last updated on clinicaltrials.gov in May 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Phuong Deleyrolle, RN
University of Florida
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.